12:00 AM
 | 
Mar 09, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alogliptin regulatory update

Takeda said FDA does not find existing data on alogliptin (SYR-322) sufficient to meet requirements set out in a December 2008 guidance on cardiovascular risk evaluation for diabetes treatments. The PDUFA date for an NDA for the selective dipeptidyl peptidase-4 (DPP-4)...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >